Publication: Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis
Issued Date
2021-02-05
Resource Type
ISSN
15365964
Other identifier(s)
2-s2.0-85101665916
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Medicine. Vol.100, No.5 (2021), e24557
Suggested Citation
Surasak Saokaew, Sukrit Kanchanasurakit, Kanitta Thawichai, Prommanee Duangprom, Monnapha Wannasri, Sirintip Khankham, Chayanis Kositamongkol, Nathorn Chaiyakunapruk, Pochamana Phisalprapa Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis. Medicine. Vol.100, No.5 (2021), e24557. doi:10.1097/MD.0000000000024557 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78450
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis
Other Contributor(s)
University of Phayao
The University of Utah
Monash University Malaysia
Faculty of Medicine Siriraj Hospital, Mahidol University
Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN
Center of Health Outcomes Research and Therapeutic Safety (Cohorts
School of Pharmacy
Division of Pharmacy Practice
Phrae Hospital
The University of Utah
Monash University Malaysia
Faculty of Medicine Siriraj Hospital, Mahidol University
Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN
Center of Health Outcomes Research and Therapeutic Safety (Cohorts
School of Pharmacy
Division of Pharmacy Practice
Phrae Hospital
Abstract
BACKGROUND: Controversy remains concerning the association of the all-cause mortality risk of hospitalized cardiovascular disease (CVD) patients with non-alcoholic fatty liver disease (NAFLD). This study investigated the risks of all-cause mortality among hospitalized CVD patients with NAFLD. METHODS: We used related keywords to search for studies in 3 electronic databases: PubMed, EMBASE, and Cochrane Library. All eligible studies published up to April 2020 were reviewed. The findings of those studies reporting the mortality outcomes of hospitalized CVD patients with and without NAFLD were examined, and the various study results were pooled and analyzed using a random-effects model. A quality assessment using the Newcastle-Ottawa scale was performed on the studies selected for inclusion in a meta-analysis. RESULTS: A total of 2135 studies were found, of which 3 were included in this meta-analysis. All studies were considered good quality. The mean age of the patients in the analysis was 73 years, and about half of them were men. The comorbidities reported were hypertension, diabetes mellitus, and dyslipidemia. The results showed that hospitalized CVD patients with NAFLD were at a significantly higher risk of all-cause mortality than non-NAFLD patients (adjusted hazard ratio of 2.08 [95% confidence interval, 1.56-2.59], P < .001). The included studies showed low heterogeneity (I2 = 0.0%, P = .473), and Begg and Egger tests revealed no apparent publication bias (P = .327 and P = .682, respectively). CONCLUSIONS: Hospitalized CVD patients with NAFLD were at a higher risk of all-cause mortality than those without NAFLD. More studies that further explore this association are needed.